Finance News – U.S.
What is your interest today?
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s Evernorth division reached an agreement that aims to reduce out-of-pocket expenses for employers and employees on certain weight management medications from Eli Lilly and N...
Read Full Article →Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →Eli Lilly stock sinks as pharma misses out on the market rally
Eli Lilly experienced a notable decline in share value as broader pharmaceutical stocks failed to benefit from the market’s upward movement, influenced by new government policies o...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Here’s how much extra weight is lost with Zepbound over Wegovy
A recent comparison of two popular weight-loss medications highlighted a measurable difference in effectiveness, potentially influencing market share and revenue for the companies...
Read Full Article →Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer...
Eli Lilly experienced a significant increase in sales attributed to strong demand for its weight loss and diabetes medications, yet adjusted its profit forecast following a recent...
Read Full Article →